Treatment of CLL with Mutated IGHV Status and No TP53 Mutation in a Medically Fit Patient

Molecular and cytogenetic profiling are central to treatment selection in CLL. This protocol addresses a well-defined subgroup: patients with mutated IGHV status, confirmed absence of TP53 mutation and del(17p), who are medically fit.

Clinical Scenario

Active CLL with mutated IGHV status, without TP53 mutation and without del(17p), in a medically fit patient. IGHV mutation status is a key prognostic and predictive factor that directly informs the appropriate treatment path in this setting.

Treatment Approach

For eligible patients in this molecular subgroup, the protocol addresses the role of advanced cellular therapy — including transplantation-based approaches and investigational options within clinical trials. Eligibility criteria, sequencing, and the complete decision algorithm are detailed in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

CLL with mutated IGHV status and without TP53 mutation or del(17p) (if there was similar efficacy, panel is giving preference to time-limited therapies):

Fit patients: CIT according to age (FCR or BR) or ibrutinib [I, A]. Venetoclax plus obinutuzumab might be an alternative to BTKis, but data for fit patients are still pending [III, A].

Allogeneic stem cell transplantation (alloSCT) should be considered in:

Patients refractory to CIT and to novel inhibitor therapy, even for patients with a higher risk of non-relapse mortality [haematopoietic cell transplant comorbidity index (HCT-CI) score of 3] [III, B];

Treatment with chimeric antigen receptor T (CAR-T) cells or bi-specific T-cell engager (BiTE) antibodies within clinical trials could be an alternative to alloSCT for all three groups [V, B].

View source ↗